Hofseth BioCare ASA – OSE:HBC.OL
Hofseth BioCare ASA stock price today
Hofseth BioCare ASA stock price monthly change
Hofseth BioCare ASA stock price quarterly change
Hofseth BioCare ASA stock price yearly change
Hofseth BioCare ASA key metrics
Market Cap | 1.10B |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -0.24 |
Revenue | 200.66M |
EBITDA | -50.57M |
Income | -97.85M |
Revenue Q/Q | 16.37% |
Revenue Y/Y | 49.26% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | -25.21% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeHofseth BioCare ASA stock price history
Hofseth BioCare ASA stock forecast
Hofseth BioCare ASA financial statements
| Jun 2023 | 52.94M | 5.76M | 10.89% |
|---|---|---|---|
| Sep 2023 | 49.73M | -22.71M | -45.67% |
| Dec 2023 | 45.88M | -51.89M | -113.09% |
| Mar 2024 | 52.09M | -29.00M | -55.68% |
| Jun 2023 | 410959000 | 294.28M | 71.61% |
|---|---|---|---|
| Sep 2023 | 401982000 | 307.92M | 76.6% |
| Dec 2023 | 390119000 | 348.97M | 89.45% |
| Mar 2024 | 390714000 | 235.04M | 60.16% |
| Jun 2023 | 3.15M | -2.75M | -6.53M |
|---|---|---|---|
| Sep 2023 | 11.02M | -8.07M | -5.24M |
| Dec 2023 | -24.41M | -8.33M | 42.21M |
| Mar 2024 | -22.74M | -1.65M | 22.66M |
Hofseth BioCare ASA alternative data
| Aug 2023 | 56 |
|---|---|
| Sep 2023 | 56 |
| Oct 2023 | 56 |
| Nov 2023 | 56 |
| Dec 2023 | 56 |
| Jan 2024 | 56 |
| Feb 2024 | 56 |
| Mar 2024 | 56 |
| Apr 2024 | 56 |
| May 2024 | 69 |
| Jun 2024 | 69 |
| Jul 2024 | 69 |
Hofseth BioCare ASA other data
-
What's the price of Hofseth BioCare ASA stock today?
One share of Hofseth BioCare ASA stock can currently be purchased for approximately $7.1.
-
When is Hofseth BioCare ASA's next earnings date?
Unfortunately, Hofseth BioCare ASA's (HBC.OL) next earnings date is currently unknown.
-
Does Hofseth BioCare ASA pay dividends?
No, Hofseth BioCare ASA does not pay dividends.
-
How much money does Hofseth BioCare ASA make?
Hofseth BioCare ASA has a market capitalization of 1.10B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 61.79% to 194.87M US dollars.
-
What is Hofseth BioCare ASA's stock symbol?
Hofseth BioCare ASA is traded on the OSE under the ticker symbol "HBC.OL".
-
What is Hofseth BioCare ASA's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Hofseth BioCare ASA?
Shares of Hofseth BioCare ASA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Hofseth BioCare ASA have?
As Jul 2024, Hofseth BioCare ASA employs 69 workers, which is 23% more then previous quarter.
-
When Hofseth BioCare ASA went public?
Hofseth BioCare ASA is publicly traded company for more then 13 years since IPO on 2 Dec 2011.
-
What is Hofseth BioCare ASA's official website?
The official website for Hofseth BioCare ASA is hofsethbiocare.no.
-
How can i contact Hofseth BioCare ASA?
Hofseth BioCare ASA can be reached via phone at +47 73 10 22 00.
Hofseth BioCare ASA company profile:
Hofseth BioCare ASA
hofsethbiocare.noOSE
56
Biotechnology
Healthcare
Hofseth BioCare ASA engages in providing value added biomarine ingredients for human and animal applications in Norway and internationally. Its products include Brilliant salmon oil; OmeGo salmon oil for the maintenance of healthy cholesterol and cardiovascular function; ProGo, a salmon protein hydrolysate powder used as a fast absorbing protein supplement; CalGo, a marine calcium powder produced to support cartilage function and joint health; CollaGo, a collagen peptide powder to enhance the beauty of hair, skin, and nails; and PetGo, a non-soluble protein. The company distributes its products through distributors, agents, and its own sales force. It has a research agreement with Stanford University School of Medicine for pre-clinical and clinical research on necrotizing enterocolitis and irritable bowel syndrome. The company was founded in 2000 and is headquartered in Ålesund, Norway.
Ålesund, 6003
:
:
:
